GlassScriptPhysician profile
Robert Christopher Bowers
NPI 1841725058
$2,062.82
in general payments reported to CMS, 2019-2025
20 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $246 · 2021: $523 · 2022: $41.83 · 2023: $578 · 2024: $443 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $442.60 | 2021-2024 | Vistaseal, Stratafix, Enseal |
| Intuitive Surgical, INC. | $362.10 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $245.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $224.14 | 2021-2023 | Lynparza, Breztri |
| Sage Therapeutics, LLC | $135.25 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $114.67 | 2023-2025 | |
| Organon LLC | $86.98 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $76.68 | 2023-2024 | Myfembree |
| Pfizer INC. | $65.77 | 2023 | |
| Astellas Pharma US INC | $61.64 | 2025 | Veozah |
| Abbvie INC. | $59.57 | 2021-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $35.40 | 2024-2025 | Gardasil 9, Gardasil |
| Minerva Surgical, INC | $28.32 | 2023-2024 | |
| Meditrina | $24.95 | 2023 | |
| Supernus Pharmaceuticals, INC. | $19.47 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.17 | 2024 | Wegovy |
| Dynavax Technologies Corporation | $16.47 | 2023 | Heplisav-B |
| Daiichi Sankyo INC. | $16.32 | 2024 | Injectafer |
| Exact Sciences Corporation | $15.13 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $14.35 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.